Response to azolic antifungal agents for treating feline sporotrichosis
- S. A. Pereira, DVM, PhD1,
- S. R. L. Passos, MD, PhD1,
- J. N. Silva, DVM1,
- I. D. F. Gremião, DVM, MSc1,
- F. B. Figueiredo, DVM, PhD1,
- J. L. Teixeira, MSc, RPh1,
- P. C. F. Monteiro, MD1 and
- T. M. P. Schubach, DVM, PhD1
- 1 Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ 21040-900, Brazil
- E-mail for correspondence: sandro.pereira{at}ipec.fiocruz.br
Abstract
The effectiveness and safety of treatment with ketoconazole and itraconazole were compared in 773 sporotrichosis-infected cats over a four-year period (2002 to 2005). Five hundred and ninety-eight cats received oral ketoconazole and 175 received oral itraconazole. Treatment was successful in 238 (30.8 per cent) cats, of which 171 (28.6 per cent) of 598 received 13.5 to 27.0 mg/kg/day ketoconazole and 67 (38.3 per cent) of 175 received 8.3 to 27.7 mg/kg/day itraconazole. Adverse effects were reported in 306 (39.6 per cent) of the cats, 105 (13.6 per cent) died and 430 (55.6 per cent) dropped out of treatment or were still under treatment at the time of data analysis.
- British Veterinary Association. All rights reserved.
